Stocky turns companies like SynAct Pharma AB into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. SYNACT.ST scores 26/100 on Value Compounder metrics, signaling modest cash generation and limited competitive durability. Leadership Alignment (45/100) reflects moderate ownership stakes and governance concerns. The Vulnerability Index flags material structural risks that warrant close monitoring before building conviction. Limited margin of safety at current levels.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for SynAct Pharma AB:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 42/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates SynAct Pharma AB (SYNACT.ST) at 42/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. SYNACT.ST scores 26/100 on Value Compounder metrics, signaling modest cash generation and limited competitive durability. Leadership Alignment (45/100) reflects moderate ownership stakes and governance concerns. The Vulnerability
SYNACT.ST's current Stocky Verdict is 42/100, placing it in the "Cautious" band. This composite combines a 26/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for SynAct Pharma AB yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
SynAct Pharma AB scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
SynAct Pharma AB's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to SynAct Pharma AB.
Sign up free and unlock the full analysis on SYNACT.ST — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for SYNACT.ST in the app.
